Analysis of curative effect of trimetazidine in the treatment of coronary heart disease patients with heart failure
10.3760/cma.j.issn.1008-6706.2017.05.001
- VernacularTitle:曲美他嗪治疗冠心病心力衰竭患者效果分析
- Author:
Yuguo SU
- Keywords:
Heart Failure;
Coronary Artery Disease Trimetazidine;
Cardiac Function Tests
- From:
Chinese Journal of Primary Medicine and Pharmacy
2017;24(5):641-644,645
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical effect of trimetazidine in the treatment of coronary heart disease(CHD)patients with heart failure.Methods 80 CHD patients with heart failure cases in our hospital from April 2015 to January 2016 were selected as the research subjects.According to the random lottery method,they were divided into two groups.The control group(n =40)adopted routine comprehensive treatment,the treatment group(n =40)was given trimetazidine on the basis of conventional treatment.The clinical curative effect and heart function index before and after the treatment,exercise tolerance and the change of vascular endothelial function were compared between the two groups.Results The total effective rate of the treatment group was 97.50%(39 /40),which was higher than 77.50%(31 /40)of the control group(χ2 =3.98,P =3.98).After treatment,the systolic blood pressure, left ventricular end systolic diameter and left ventricular end -diastolic diameter in the treatment group were less than the control group,while the left ventricular ejection fraction was greater than the control group,the differences between the two groups were statistically significant (all P <0.01 ),the above index before treatment had no statistically significant differences (all P >0.05 ).The 6 min walking distance of the treatment group after treatment was (375.67 ±28.48)m,which of the control group was (306.18 ±25.71)m,the difference was statistically significant (t =11.451,P =11.451),and the 6 min walking distance before treatment had no statistically significant difference (t =0.013,P =0.013).In the treatment group after treatment,the vascular endothelial function index was (2.32 ± 0.36 )mg/L,which of the control group was (2.95 ±0.16 )mg/L,the difference was statistically significant (t =10.114,P =10.114),while the two groups before treatment had no statistically significant difference in endothelial function index (t =0.126,P =0.126).Conclusion The clinical effect of trimetazidine in the treatment of CHD patients with heart failure is sure,and it can effectively relieve symptoms of heart failure patients,improve the cardiac function,improve their exercise tolerance,which can be used as an ideal drug in CHD patients with heart failure.
